Definium Therapeutics (NASDAQ:DFTX) Rating Increased to Hold at Wall Street Zen

Wall Street Zen upgraded shares of Definium Therapeutics (NASDAQ:DFTX) from a sell rating to a hold rating in a research report report published on Sunday.

A number of other brokerages have also commented on DFTX. Oppenheimer set a $60.00 target price on Definium Therapeutics and gave the company an “outperform” rating in a research report on Monday, June 22nd. Weiss Ratings reiterated a “sell (d-)” rating on shares of Definium Therapeutics in a report on Friday, July 17th. Citigroup reiterated a “buy” rating on shares of Definium Therapeutics in a report on Monday, June 22nd. Stifel Nicolaus raised their price objective on Definium Therapeutics from $30.00 to $60.00 and gave the company a “buy” rating in a research note on Wednesday, July 8th. Finally, Canaccord Genuity Group set a $58.00 price objective on Definium Therapeutics and gave the company a “buy” rating in a report on Tuesday, June 30th. Two equities research analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Definium Therapeutics currently has a consensus rating of “Buy” and an average price target of $51.15.

Definium Therapeutics Stock Performance

NASDAQ:DFTX opened at $43.17 on Friday. Definium Therapeutics has a 12 month low of $7.96 and a 12 month high of $49.20. The company has a current ratio of 4.69, a quick ratio of 4.69 and a debt-to-equity ratio of 0.15. The stock has a market capitalization of $4.30 billion, a price-to-earnings ratio of -17.34 and a beta of 2.20. The firm has a fifty day simple moving average of $33.64 and a two-hundred day simple moving average of $23.90.

Definium Therapeutics (NASDAQ:DFTX) last announced its quarterly earnings data on Friday, May 8th. The company reported ($0.71) earnings per share for the quarter, missing the consensus estimate of ($0.48) by ($0.23). Analysts expect that Definium Therapeutics will post -2.27 EPS for the current fiscal year.

Insider Buying and Selling at Definium Therapeutics

In related news, insider Matthew T. Wiley sold 2,867 shares of the company’s stock in a transaction dated Thursday, June 25th. The shares were sold at an average price of $45.03, for a total value of $129,101.01. Following the sale, the insider owned 174,633 shares in the company, valued at $7,863,723.99. This represents a 1.62% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CFO Brandi Roberts sold 3,013 shares of the firm’s stock in a transaction dated Thursday, June 25th. The shares were sold at an average price of $45.03, for a total transaction of $135,675.39. Following the completion of the transaction, the chief financial officer directly owned 209,487 shares in the company, valued at approximately $9,433,199.61. The trade was a 1.42% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 48,096 shares of company stock valued at $2,165,763 over the last three months. Corporate insiders own 2.40% of the company’s stock.

Institutional Trading of Definium Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in DFTX. Russell Investments Group Ltd. lifted its holdings in shares of Definium Therapeutics by 110.4% in the second quarter. Russell Investments Group Ltd. now owns 3,817 shares of the company’s stock valued at $25,000 after purchasing an additional 2,003 shares in the last quarter. BNP Paribas Financial Markets boosted its position in shares of Definium Therapeutics by 56.0% during the second quarter. BNP Paribas Financial Markets now owns 8,417 shares of the company’s stock valued at $55,000 after buying an additional 3,020 shares during the last quarter. Flagship Harbor Advisors LLC bought a new stake in Definium Therapeutics during the fourth quarter worth $117,000. Caxton Associates LLP bought a new stake in Definium Therapeutics during the third quarter worth $126,000. Finally, Mercer Global Advisors Inc. ADV raised its position in Definium Therapeutics by 10.5% in the 3rd quarter. Mercer Global Advisors Inc. ADV now owns 21,931 shares of the company’s stock valued at $259,000 after buying an additional 2,079 shares during the last quarter. 27.91% of the stock is owned by institutional investors.

About Definium Therapeutics

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.